By Frances Howard One of the leading causes of death among women and men in the United States is that of coronary heart disease. Most ofte...
One of the leading causes of death among women and men in the United States is that of coronary heart disease. Most often, the condition is treated through a number of lifestyle changes, medications and surgeries. While this is the case, there are some individuals whom have now turned to oral chelation therapy which uses ethylene diamine tetra-acetic acid or EDTA, a controversial though complementary treatment.
In this type of therapy, an ethylene diamine tetra-acetic acid or EDTA solution, not yet approved by the United States Food and Drug Administration is often used to provide relief. Even without such approval, a study in 2007 showed that there were over 10,000 people in the United States opting for this treatment. Ultimately, the substance provides a chemical process using molecules to bind and hold metals and minerals in the body in place.
Originally used to eliminate excess waste and toxic metals from the body, the treatment is far from new. For, EDTA has also been used to eliminate iron overload and treat lead poisoning in Western medicine. Whereas, when using the process to treat heart disease, a health care provider carefully provides injections of disodium EDTA into the veins over the course of 30 or more infusions generally on a weekly basis. After which, the treatment moves to a maintenance phase in which infusions are provided on an as needed basis.
To help determine whether this therapy might be helpful in treating heart attack victims, two organizations supported a trial. The purpose of the trial, to determine the success rate of the therapy on individuals with a previous history of heart attacks and heart disease. The results showed that the infusions were successful in dropping the number of occurrences, though only in people whom were also diabetic.
During the study, individuals with diabetes made up approximately one third of participants. During the trial, diabetics showed a forty one percent reduction in cardiovascular events and a forty percent risk of death from heart disease, stroke or non-fatal heart attacks. In addition, fifty two percent experienced a reduction in repetitive heart attacks and a forty three percent reduction in death from other causes. Whereas, individuals whom did not have diabetes did not experience any significant benefits from the disodium EDTA infusions.
The trial also included individuals whom were taking high dose vitamins and minerals while receiving chelation therapy. In most cases, the combination provided the highest drops in heart attack risks among participants versus others whom were only provided placebos.
Over the course of the study, 16% of individuals receiving chelation therapy and 15% of individuals receiving placebos asked to stop the infusions due to adverse effects. Overall, there were four major events, two deaths, one in each the placebo and chelation group and minor side effects. To date, the primary side effect appears to be burning at or near the injection site during the infusion process.
More research is needed before it can be determined if chelation therapy provides the best treatment for heart attack victims, especially those living with diabetes. As a result, the results reflected in this article or current research studies do not provide enough detailed information in order to make a final decision. Regardless, researchers and scientists are hopeful that future studies and trials will provide more positive results.
In this type of therapy, an ethylene diamine tetra-acetic acid or EDTA solution, not yet approved by the United States Food and Drug Administration is often used to provide relief. Even without such approval, a study in 2007 showed that there were over 10,000 people in the United States opting for this treatment. Ultimately, the substance provides a chemical process using molecules to bind and hold metals and minerals in the body in place.
Originally used to eliminate excess waste and toxic metals from the body, the treatment is far from new. For, EDTA has also been used to eliminate iron overload and treat lead poisoning in Western medicine. Whereas, when using the process to treat heart disease, a health care provider carefully provides injections of disodium EDTA into the veins over the course of 30 or more infusions generally on a weekly basis. After which, the treatment moves to a maintenance phase in which infusions are provided on an as needed basis.
To help determine whether this therapy might be helpful in treating heart attack victims, two organizations supported a trial. The purpose of the trial, to determine the success rate of the therapy on individuals with a previous history of heart attacks and heart disease. The results showed that the infusions were successful in dropping the number of occurrences, though only in people whom were also diabetic.
During the study, individuals with diabetes made up approximately one third of participants. During the trial, diabetics showed a forty one percent reduction in cardiovascular events and a forty percent risk of death from heart disease, stroke or non-fatal heart attacks. In addition, fifty two percent experienced a reduction in repetitive heart attacks and a forty three percent reduction in death from other causes. Whereas, individuals whom did not have diabetes did not experience any significant benefits from the disodium EDTA infusions.
The trial also included individuals whom were taking high dose vitamins and minerals while receiving chelation therapy. In most cases, the combination provided the highest drops in heart attack risks among participants versus others whom were only provided placebos.
Over the course of the study, 16% of individuals receiving chelation therapy and 15% of individuals receiving placebos asked to stop the infusions due to adverse effects. Overall, there were four major events, two deaths, one in each the placebo and chelation group and minor side effects. To date, the primary side effect appears to be burning at or near the injection site during the infusion process.
More research is needed before it can be determined if chelation therapy provides the best treatment for heart attack victims, especially those living with diabetes. As a result, the results reflected in this article or current research studies do not provide enough detailed information in order to make a final decision. Regardless, researchers and scientists are hopeful that future studies and trials will provide more positive results.
About the Author:
When you are looking for information about oral chelation, come to our web pages today. More details are available at http://www.heartdrop.com now.
Aucun commentaire